Drug-induced bone loss

Osteoporosis International

Volumn 11, Issue 8, 2000, Pages 637-659

  Tannirandorn, P ^a   Epstein, S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aluminium hydroxide; Antacids; Anticoagulants; Anticonvulsants; Antineoplastic agents; Antipsychotic agents; Aromatase inhibitors; Bisphosphonates; Bone; Bone density; Cholestyramine; Cyclosporin A; Drugs induced; Ethanol; Etidronate disodium; Fluorides; Fractures; Glucocorticoids; Gonadorelin; Iatrogenic disease; Immunosuppressive agents; Levothyroxine; Lithium; Medroxyprogesterone; Methotrexate; Neuroleptics; Os teomalacia; Osteoporosis; Saccharated ferric oxide

Indexed keywords

ALCOHOL; ALENDRONIC ACID; ALUMINUM; ANASTROZOLE; ANION EXCHANGE RESIN; ANTACID AGENT; ANTICONVULSIVE AGENT; AROMATASE INHIBITOR; BUTYROPHENONE DERIVATIVE; CYCLOSPORIN A; DEFEROXAMINE; ETIDRONIC ACID; FERRIC OXIDE; FLUORIDE SODIUM; GLUCOCORTICOID; GONADORELIN AGONIST; HEPARIN; LETROZOLE; LEVOTHYROXINE; LITHIUM CARBONATE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; NEUROLEPTIC AGENT; PAMIDRONIC ACID; PHENOTHIAZINE; TIBOLONE; TSUKUBAENOLIDE; UNINDEXED DRUG; VALPROIC ACID; VOROZOLE;

AGED; ALCOHOLISM; BONE ATROPHY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; MENOPAUSE; OSTEOMALACIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADULT; HUMAN; OSTEOMALACIA; OSTEOPOROSIS;

EID: 0033789066     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980070062     Document Type: Review

References (514)

1. Prophylaxis and treatment of osteoporosis
2. The prevention and treatment of osteoporosis
3. Population-based study of survival after osteoporotic fractures
4. The worldwide problem of osteoporosis: Insights afforded by epidemiology
5. Costs and health effects of osteoporotic fractures
6. How many women have osteoporosis?
7. Iatrogenic osteoporosis
8. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis
9. Steroid-induced fractures and bone loss in patients with asthma
10. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
11. Glucocorticoid-induced osteoporosis: Pathogenesis and management
12. Fractures in rheumatoid arthritis: An evaluation of associated risk factors
13. The basophil adenomas of the pituitary body and their clinical manifestations
14. Corticosteroid induced osteoporosis: Followup over 3 years
15. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases
16. Glucocorticoids and bone
17. Generalized bone loss in patients with early rheumatoid arthritis
18. Corticosteroid-induced bone loss: A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography
19. Users of low dose glucocorticoids have increased bone loss rates: A longitudinal study
20. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: Effect of low dose corticosteroids
21. The effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis
22. Bone loss in adults receiving alternate day glucocorticoid therapy: A comparison with daily therapy
23. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids
24. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids
25. Inhaled corticosteroid: Effect on bone?
26. A comparison of the safety and efficacy of fluticasone propionate (1 mg/day and 2 mg/day) and budesonide (1.6 mg/day) in the treatment of severe asthma
27. Fluticasone propionate does not influlence bone metabolism in contrast to beclomethasone dipropionate
28. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids
29. Effect of chronic corticosteroid administration on diaphyseal and metaphysical bone mass
30. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders
31. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: A relatively bone-sparing effect of deflazacort
32. Deflazacort: A review of its pharmacological properties and therapeutic efficacy
33. Serum osteocalcin (bone Gla-portein) following corticosteroid therapy in post-menopausal women with rheumatoid arthritis: Comparison of the effect of prednisone and deflazacort
34. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: A double-blind study on the high-dose, long-term effects of prednisone versus deflazacort
35. Effects of deflazacort versus prednisone on bone mass, body composition and lipid profile: A randomized, double-blind study in kidney transplant patients
36. Deflazacort in pediatric rheumatic diseases needs a frequent follow-up of bone densitometry
37. Long-term treatment of chronic inflammatory disorders with deflazacort
38. Bioequivalence of deflazacort and prednisone in the treatment of idiopathic nephrotic syndrome: A pilot study
39. A longterm prospective study of the equipotency between deflazacort and prednisolone in the treatment of patients with polymyalgia rehumatica
40. 3 receptors in cultured rat osteoblast-like cells: Glucocorticoid treatment increases receptor content
41. 3 receptors in cultured mouse bone cells
42. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells
43. 3 in monocytes from normal human subjects
44. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH m ROS 17/2.8 and OK cells
45. Effects of short-term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man
46. Effect of cortisone treatment on the active transport of calcium by the small intestines
47. Altered mineral metabolism in glucocorticoid-induced osteopenia: Effect of 25-hydroxyvitamin D administration
48. Effects of cortisone administration on the metabolism and localization of 25-hydroxycholecalciferol in the rat
49. Intestinal calcium absorption in exogenous hypercortisonism: Role of 25-hydroxyvitamin D and corticosteroid dose
50. Production, degradation and circulating levels of 1,25-dihydroxyvitamin D in health and chronic glucocorticoid excess
51. 3 and glucocorticoids
52. Tissue-specific regulation of shell gland calbindin D28K biosynthesis by estradiol in precociously matured, vitamin D-depleted chicks
53. Serum 25-hydroxyvitamin D concentrations in patients receiving chronic corticosteroid therapy
54. Malabsorption of calcium in corticosteroid-induced osteoporosis
55. The effect of long- and short-term corticosteroid on plasma calcitonin and parathyroid hormone levels
56. Effect of glucocorticoids on function of the parathyroid glands in man
57. Ostcopenia in patients with rehumatic diseases: Principles of diagnosis and therapy
58. Calcium and phosphorus homeostasis in man: Effect of corticosteroids
59. Osteoporosis after cardiac transplantation
60. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy
61. Corticosteroid and bone
62. Pathogenesis and treatment of steroid osteoporosis
63. Corticosteroid-induced bone loss in men
64. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on kidney and skeleton
65. Reversible gonadotrophin deficiency in male Cushing's disease
66. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects
67. Cortisol-induced suppression of plasma testosterone in normal adult males
68. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells
69. Reduction of serum testosterone levels during chronic glucocorticoid therapy
70. Effect of glucocorticoids on plasma testosterone in men
71. Hormonal status in normal, osteoporotic and corticosteroid-treated postmenopausal women
72. Bone histomorphometry in glucocorticoid-induced osteoporosis
73. Effect of glucocorticoids on fetal rat bone collagen synthesis in vitro
74. Inhibition of collagen and sulfated glycosaminoglycan synthesis in neonatal mouse dermal fibroblasts by corticosterone
75. Cortisol decreases bone formation by inhibiting periosteal cell proliferation
76. Histomorphometric profile, pathophysiology and reversibility of corticosteroid induced osteoporosis
77. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis
78. The effect of cortisone on lamellar osteoblastic activity
79. Glucocorticoids inhibit the attachment of osteoblasts to bone extracellular matrix proteins and decrease beta 1-integrin levels
80. Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro
81. Down-regulation of c-fos and cell growth with upregulation of p53 oncogene in glucocorticoid-treated osteoblasts
82. Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae
83. 2 and cortisol in bone growth in organ culture
84. Effects of parathyroid hormone and cortisol on prostaglandin production by neonatal rat calvaria in vitro
85. Glucocorticoid control of transforming growth factor beta 1 activity and binding in osteoblast-enriched cultures from fetal rat bone
86. Insulin-like growth factor I enhances the formation of type I collagen in hydrocortisone-treated human osteoblasts
87. Insulin-like growth factors and their binding proteins: Biological actions
88. Insulin-like growth factors and bone: The osteoporosis connection
89. The role of insulin-like growth factors and binding proteins in bone cell biology
90. Glucocorticoid regulation of insulin-like growth factor binding protein expression in normal human osteoblast-like cells
91. Insulin-like growth factors in health and disease
92. Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men
93. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action
94. Inhibitory insulin-like growth factor binding-protein: Cloning, complete sequence, and physiological regulation
95. Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6
96. Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast
97. Cortisol inhibits the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures by transcriptional mechanism
98. Cortisol enhances the transcription of insulin-like growth factor binding protein-6 in cultured osteoblasts
99. Glucocorticoid-induced activation of latent transforming growth factor-β by normal human osteoblast-like cells
100. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1 and IL-6 and INF-gamma
101. Skeletal growth factors
102. Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis
103. The hormonal and local regulation of bone formation
104. Interleukin-11: A new cytokine critical for osteoclast development
105. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis
106. The course of biochemical parameters of bone turnover during treatment with corticosteroids
107. Cortisol increases interstitial collagenase expression in osteoblast by post-transcriptional mechanisms
108. Increased osteoclast development after estrogen loss: Mediation by interluekin-6
109. The pathophysiologic roles of interleukin-6 in human disease
110. Cytokines, oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130)
111. Glucocorticoids stimulate resorption in fetal rat parietal bone in vitro
112. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: Potential mechanisms of their deleterious effects on bone
113. Serum osteocalcin in the assessment of corticosteroid-induced osteoporosis: Effect of long and short term corticosteroid treatment
114. Corticosteroid-induced osteoporosis
115. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton
116. Combined treatment with cyclosporin A and cortisone acetate minimizes the adverse bone effects of either agent alone
117. Metabolic bone disease
118. Reversibility of steroid-induced osteoporosis
119. Recovery from steroid-induced osteoporosis
120. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate
121. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids
122. Testosterone therapy in glucocorticoid-treated men
123. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women
124. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss
125. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylindene)-1,1-bis-phosphonate (APD)
126. Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: Three years of follow-up
127. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss
128. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis
129. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis
130. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol, and calcitonin
131. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial
132. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: A 3 year followup
133. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid-treated patients
134. Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate
135. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis
136. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica
137. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients
138. Nasal administration of salmon calcitonin of prevention of glucocorticoid-induced osteoporosis in children
139. A comparison of the effects of etidronate, pamidronate, clodronate and calcium on bone density in patients with corticosteroid-dependent lung disease
140. Effect of intermittent cyclic etidronate (ICT) therapy for glucocorticoid-induced osteoporosis in rheumatoid arthritis (RA): Interim analysis
141. Cyclical etidronate increases bone mass in patients with established steroid-induced bone osteoporosis
142. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis
143. Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D and a diphosphonate
144. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma: A one-year follow-up study
145. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: A two year follow up study
146. Salmon calcitonin in the therapy of corticoid-induced osteoporosis
147. Corticosteroid-induced osteoporosis: Effects of slow-release fluoride
148. In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: A double-masked randomized study
149. Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis
150. Prospective comparison of bone loss with tacrolimus and cyclosporin A after organ transplantation
151. Organ transplantation and osteoporosis
152. Cyclosporine
153. The cytokine network
154. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
155. Peptide regulatory factors: Multifunctional mediators of cell growth and differentiation
156. Cyclosporin-sensitive and cyclosporin-insensitive modes of B cells stimulation
157. Inhibition of cytokine production by cyclosporin A and G
158. Modulation of interleukin-1 effects on bone by cyclosporine
159. Cyclosporine A inhibits calcemic hormone-induced bone resorption in vitro
160. T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia
161. T-cells medicate a stimulatory effect of cyclosporin A on human osteoclastogenesis while immature osteoclast precursors are directly regulated by glucocorticoids
162. Cyclosporine-A in vivo produces severe osteopenia in the rat: Effect of dose and duration of administration
163. 3 in the rat and mouse
164. Cyclosporin A in the oophorectomized rat: Unexpected severe bone resorption
165. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat
166. Effect of cyclosporine A on male reproduction in rats
167. The role of testosterone in cyclosporine-induced osteopenia
168. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients
169. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation
170. Mechanisms of boss after cardiac transplantation
171. Fracture after cardiac transplantation: A prospective longitudinal study
172. Bone loss after liver transplantation
173. Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with cyclosporin
174. Relationship of glucocorticoid dosage to serum bone Glaprotein concentration in patients with rheumatologic disorders
175. The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects
176. Effect of renal function on plasma levels of bone Gla-protein
177. Potential protection by cyclosporin against glucocorticoid effects on bone
178. Rapid loss of vertebral mineral density after renal transplantation
179. Bone histomorphometry after cardiac transplantation
180. Bone loss after cardiac transplantation: A prospective study
181. Bone loss and turnover after cardiac transplantation
182. Intermittent etidronate and corticosteroid-induced osteoporosis
183. Calcitonin and bisphosphonates treatment in bone loss after liver transplantation
184. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
185. 1β-Estradiol prevents osteopenia in the oophorectomized rat treated with cyclosporin-A
186. Salmon calcitonin prevents cyclosporin-A-induced high remover bone loss
187. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation
188. 2 and risedronate administration is maintained after their withrawal in older female rats
189. 2 alone in maintaining newly added bone in the cortical bone site after withdrawal in older intact rats
190. 2 alone treatment in cortical bone of ovariectomized rats
191. 2 increases the skeletal response to mechanical loading
192. Raloxifene analog (LY117018 HCL) ameliorates cyclosporin A-induced osteopeloss nia in oopphorectomized rats
193. Transcription-modulating drugs: Mechanism and selectivity
194. Next generation of SERMs being seen in clinic
195. Raloxifene: A selective estrogen receptor modulator
196. The deleterious effects of long-term cyclosporin A, cyclosporin G, and FK506 on bone mineral metabolism in vivo
197. Evidence that cyclosporine G is less deleterious to rat bone in vivo than cyclosporine A
198. Rapamycin: A bone sparing immunosuppressant?
199. Mycophenolate mofetil: A promising new immunosuppressant that does not cause bone loss in the rat
200. Mineral and bone metabolism in thyroid disease: A review
201. Trabecular bone remodeling and bone balance in hyperthyroidism
202. Spinal bone mineral content in myxoedema and thyrotoxicosis: Effects of thyroid hormone(s) and antithyroid treatment
203. Effects of thyroid hormone on bone and mineral metabolism
204. Bone changes in hyperthyroidism: Interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism
205. A tetracycline based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism
206. Thyroxine therapy
207. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers
208. Ionized and total serum calcium and parathyroid hormone in hyperthyroidism
209. Disturbed mineral metabolism in hyperthyroidism: Good correlation with tri-iodothyronine
210. Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism
211. Hypercalcemia of thyrotoxicosis
212. The serum calcium level and its significance in hyperthyroidism: A prospective study
213. Phosphate excretion and parathyroid function in thyrotoxicosis
214. Glucocorticoid and thyroid hormones transcriptionally regulate growth hormone gene expression
215. The effects of hypothyroidism and 2,4-dinitrophenol on growth hormone Synthesis
216. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women
217. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine
218. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine
219. Bone mineral density in postmenopausal women treated with L-thyroxine
220. Morbidity in patients on L-thyroxine: A comparison of those with a normal TSH t those with a suppressed TSH
221. Prevalence of fractures in postmenopausal women with thyroid disease
222. Thyrotoxic bone disease in women: A potentially reversible disorder
223. Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroisism
224. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma
225. Bone loss in hypothyroidism with hormone replacement: A histomorphometric study
226. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: A meta-analysis
227. Cytokines and estrogen in bone: Anti-osteoporotic effects
228. Thyroid hormone use and bone mineral density in elderly women: Effects of estrogen
229. Long-term thyroxine treatment and bone mineral density
230. Skeletal integrity in premenopausal and postmenopausal women receiving long term L-thyroxine therapy
231. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in postmenopausal women
232. Levothyroxine and osteoporosis: An end to the controversy?
233. Thyroid hormone use and fractures
234. L-Thyroxine dosage: A reevaluation of therapy with contemporary preparations
235. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic Fractures Research Group
236. Postmenopausal bone loss is prevented by teatment with low-dosage estrogen with calcium
237. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine
238. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin
239. Effect of calcium supplementation on bone loss in postmenopausal women
240. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial
241. The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat: Comparison between effects on tibiae and vertebrae
242. Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and emssenger ribonucleic acid markers of osteoblast and osteoclast function
243. Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans
244. Randomized trial of pamidronate in patients with thyroid cancer: Bone density isnot reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate
245. TSH-suppressive L-thyroxine therapy decreases bone density in the rat: Effect of hypogonadism, calcitonin
246. Is long-term levothyroxine therapy safe?
247. Drug-induced metabolic bone disease
248. A randomized controlled trial of medroxyprogesterone acetate and psychotherapy for the treatment of pelvic congestion
249. Premenstrual tension: A placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate
250. Evaluation of oral MPA in the treatment of endometriosis
251. Update on endocrine therapy for breast cancer
252. Mechanisms of action of endocrine treatment in breast cancer
253. Recent advances in endocrine therapy of breast cancer
254. The Cushing syndrome induced by medroxyprogesterone acetate
255. Progesterone as a bone-trophic hormone
256. Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rate
257. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures
258. Effects of norethisterone on bone related biochemical variables and forearm bone mineral density in postmenopausal osteoporosis
259. Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women
260. Effect of progestin therapy on corticla and trabecular bone: Comparison with estrogen
261. Bone density in women receiving depot medroxyprogesterone acetate for contraception
262. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women
263. Recovery of bone density in women who stop using medroxyprogesterone acetate
264. Prevention of bne mineral loss in postmenopausal women by norethisterone
265. Effect of progestins on bone metabolism in postmenopausal women
266. Spinal bone loss and ovulatory disturbances
267. Premenopausal ovariectomy-related bone loss: A randomized double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate
268. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy
269. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma
270. Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma
271. LHRH agonist treatment of breast cancer and gynecological malignancies
272. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism
273. Dietary calcium, sex hormones, and bone mineral density in men
274. Sex hormones and bone mineral density in elderly men
275. Gonadotropin-releasing hormone agonists and the skeleton
276. The prevention of bone loss in young women treated with GnRH analogues with 'add-back' estrogen therapy
277. Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis
278. Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment
279. Strategies to protect bone mass in the older patient with epilepsy
280. Biological effects of androgens and identification of specific dihydrotestosterone-binding sites in cultured human fetal epiphyseal chodrocytes
281. Identification of androgen receptors in normal human osteoblast-like cells
282. Evidence for a direct in vitro action of sex steroids on rabbit cartilage cells during skeletal growth: Influence of age and sex
283. Influence of testosterone and dihydrotestosterone on bone-matrix induced endochondral bone formation
284. Studies of the mechanism by which androgens enhance mitogenesis and differentiation in bone cells
285. Androgens directly stimulate proliferation of bone cells in vitro
286. Androgen receptors in osteoblast-like cell lines
287. Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH)
288. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
289. Some atherogenic concomitants of menopause: The Framingham Study
290. Long-term and withdrawal effects of two different estrogen-progestogen combinations on lipids and lipoproteins profiles in postmenopausal women
291. Cortical remodeling following suppression of endogenous estrogen with analogs of gonadrotropin releasing hormone
292. The effects of gonadotrophin-releasing hormone agonists on iliac crest cancellous bone structure in women with endometriosis
293. Intermittent etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist
294. Aromatization of androgens is important for skeletal maintenance of aged male rats
295. Aromatase deficiency in women and men: Would you have predicted the phenotype?
296. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
297. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency
298. Heparin-induced osteoporosis: An appraisal
299. The osteoporosis of heparinotherapy and systemic mastocytosis
300. Heparin osteoporosis
301. Long-term therapy with subcutaneous heparin during pregnancy
302. Nonhemorrhagic complications of anticoagulant therapy
303. Risk of osteoporosis in patients treated with long-term intravenous heparin therapy
304. Symposium on heparin
305. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin
306. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry
307. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient
308. Multiple fractures associated with long-term sodium heparin therapy
309. Heparin induced spinal fractures
310. Heparin-induced osteopenia in pregnancy
311. Heparin modulates the response of cultured human trabecular bone cells to hormone
312. The effect of heparin and protamine on resorption of bone particles
313. Effects of heparin on osteoclast activity
314. Heparin augments osteoclast resorption-stimulating activity in serum
315. Low 1,25-dihydroxyvitamin D in heparin-induced osteopenia
316. The role of growth factors in skeletal remodeling
317. The interaction of heparin and basic fibroblast growth factor on collagen synthesis in 21-day fetal rat calvariac
318. Growth stimulation of rat calvaria osteoblastic cells by acidic fibroblast growth factor
319. Interaction of endothelial cell growth factor with heparin: Characterization by receptor and antibody recognition
320. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo
321. Prolonged heparin therapy in pregnancy causes bone demineralization
322. Heparins, coumarin, an bone density
323. Heparin-related osteoporosis in rats: A comparative study between unfractionated heparin and a low-molecular-weight heparin
324. Osteopenia in pregnancy during long-term heparin treatment: A radiological study post partum
325. Histomorphometric evaluation of reversible heparin-induced osteoporosis in pregnancy
326. Systemic mast cell disease: Analysis of 58 cases and literature review
327. Systemic mast cell disease: A clinical and hematopathological study of 26 cases
328. Systemic mastocytosis presenting as osteoporosis: A clinical and histomorphometric study
329. Heparin modulates intracellular cyclic AMP in human trabecular bone cells and adherent rheumatoid synovial cells
330. Studies of histamine in the rheumatoid joint
331. Severe osteoporosis due to systemic mast cell disease: Successful treatment with interferon alpha-2b
332. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis
333. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b
334. Warfarin use and risk for osteoporosis in elderly women
335. Norml cortical bone mass in patients after long term coumadin therapy
336. Osteopenia and bone-remodeling abnormalities in warfarin-treated lambs
337. 3-treated rats
338. Bone disease in alcohol abuse
339. Ethanol reduces bone formation and may cause osteoporosis
340. Deranged bone mineral metabolism in chronic alcoholism
341. Bone changes after alcohol abuse
342. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease
343. Demonstratioin that ethanol inhibits bone matrix synthesis and mineralization in the rat
344. Effects of alcohol abuse on bone
345. Low serum osteocalcin in acute alcohol intoxication: A direct toxic effect of alcohol on osteblasts
346. Effects of ethanol on bone cells in vitro resulting in increased resorption
347. The urinary excretion of collagen degradation markers pyridinoline and deoxypyridinoline in an experimental rat model of alcoholic bone disease
348. Ethanol activates the interleukin-6 promoter in a human bone marrow stromal cell line
349. Inhibitory effects of ethanol on the growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-I axis in the rat
350. Bone and mineral metabolism and chronic alcohol abuse
351. Parathyroid hormone secretion in magnesium deficiency
352. Free 25-hydroxyvitamin D levels are normal in subjects with liver disease and reduced total 25-hydroxyvitamin D levels
353. Gonadal consequences of alcohol abuse: Lessons from the liver
354. Clinically important effects of alcohol on endocrine
355. Transient hypoparathyroidism during acute alcohol intoxication
356. Ethanol decreases nocturnal plasma levels of thyrotropin and growth hormone but not those of thyroid hormones or prolactin in man
357. Alcohol, osteoporosis, and bone regulating hormones
358. An examination of various mechanisms for ethanol-induced testicular injury: Studies utilizing the isolated perfused rat testes
359. Bone disorder in men with chronic alcoholism: A reversible disease?
360. Bone mass improves in alcoholics after 2 years of abstinence
361. A prospective study of alcohol consumption and bone mineral density
362. Effects of alcohol ingestion on estrogens in postmenopausal women
363. Moderate alcohol consumption and estrogen levels in postmenopausal women: A review
364. Certain neuroleptics reduce bone mineralization in schizophrenic patients
365. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men
366. Endocrinological changes inpatients with sexual dysfunction under long-term neuroleptic treatment
367. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia
368. Prolactin and neuroleptic drugs
369. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism
370. Inhibitory effect of phenothiazine derivatives on bone in vivo and osteoblastic cells in vitro
371. Antiestrogen binding sites: General and comparative properties
372. Stimulation of intestinal calcium transport and bone calcium mobilization by prolactin in vitamin D-deficient rats
373. Osteoblasts are a new target for prolactin: Analysis of bone formation in prolactin receptor knockout mice
374. Osteoporosis in men with hyperprolactinemic hypogonadism
375. Bone density in amenorrheic women with and without hyperprolactinemia
376. Accelerated osteoporosis in psychiatric patients: Possible pathophysiological processes
377. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer
378. Methotrexate osteopathy in long term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis
379. 3
380. The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats
381. Methotrexate effects on heterotopic bone in rats
382. The short- and long-term effects of methotrexate on rat skeleton
383. The effects of methotrexate on the production and activity of interleukin-1
384. Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate
385. Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission
386. Fractures in children treated with methotrexate for leukemia
387. Methotrexate osteopathy
388. Methotrexate osteopathy in rheumatic disease
389. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis
390. 3H-thymidine incorporation by cell line UMR 106-01
391. Effects of aluminum on rat bone cell populations
392. Aluminum absorption and distribution: Effect of parathyroid hormone
393. Aluminum and aluminum complexes: Effect on calcium phosphate precipitation
394. Effect of aluminum and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure
395. Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosis
396. Parathyroid response to aluminium in vitro: Ultrastructural changes and PTH release
397. Suppression of parathyroid hormone secretion by aluminum
398. 3 metabolites
399. 3 in the chick
400. 3 receptors and end organ response in experimental aluminum intoxication
401. 3 in dialysis patients
402. Reduced serum levels of 1-alpha,25-dihydroxy-vitamin D during long-term parenteral nutrition
403. Calcitriol, parathyroid hormone, and accumulation of aluminum in bone in dogs with renal failure
404. Parenteral aluminum administration in the dog. II. Induction of osteomalacia and effect on vitamin D metabolism
405. Oral aluminum administration to uremic, hyperparathyroid, or vitamin D supplemented rats
406. 3
407. The natural course of dialysis osteomalacia
408. Bone disease in moderate renal failure: Cause, nature, and prevention
409. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
410. Bone histologic response to deferoxamine in aluminum-related bone disease
411. Deferoxamine-induced bone changes in haemodialysis patients: A histomorphometric study
412. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease
413. The use of deferoxamine in the management of aluminum accumulation in bone in patients with renal failure
414. Urinary aluminum excretion following renal transplantation and the effect of pulse steroid therapy
415. The efficacy of various treatment modalities on aluminum associated bone disease
416. Resolution of hypercalcemia and aluminum bone disease after renal transplantation
417. Evidence for a phosphorus-depletion syndrome in man
418. Effect of small amounts of antacids on calcium, phosphorus, and fluoride metabolism in man
419. Thrid Raymond Keating, Jr Memorial Symposium: Parathyroid hormone, calcitonin and vitamin D. Clinical consideration. II. Vitamin D - 1973
420. The role of vitamin D metabolites in bone resorption
421. Formation, mineralization, and resorption of bone in hypophosphatemic rats
422. Phosphate as a regulator of bone collagen and mineral resorption
423. Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture
424. Osteomalacia and pseudofractures caused by the ingestion of aluminum hydroxide
425. Antacid and sulcralfate-induced hypophosphatemic osteomalacia: A case report and review of the literature
426. Antacid-induced osteomalacia and nephrolithiasis
427. Drug-induced bone disease
428. Adverse effects of aluminum-containing antacids on mineral metabolism
429. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, parathyroid hormone
430. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults
431. Carbamazepine and bone mineral metabolism
432. Development of antconvulsant osteomalacia in epileptic patients on phenytoin therapy
433. Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?
434. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment
435. Rickets in children receiving anticonvulsant drugs: Biochemical and hormonal markers
436. 3H in rat liver
437. 2
438. Phenobarbital-induced alterations in vitamin D metabolism
439. Bone complications of anticonvulsants
440. Osteomalacia with long-term anticonvulsant therapy in epilepsy
441. Representativity of regional to total bone mineral in healthy subjects and 'anticonvulsant treated' epileptic patients: Measurement by single- and dual-photon absorptiometry
442. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy
443. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs
444. Disturbances of calcium metabolism by anticonvulsant drugs
445. Effects of anticonvulsant drug therapy on bone mineral density in a pediatric population
446. Effects of diphenylhydantoin on synthesis of collagen and noncollagen proteins in tissue culture
447. Osteogenic actions of phenytoin in human bone cells are mediated in part by TGF-beta 1
448. Phenytoin at micromolar concentrations is an osteogenic agent for human-mandible-derived bone cells in vitro
449. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat
450. A quantitative determination of anticonvulsant-induced bone demineralization by an improved x-ray densitometry technique, Neuroradiology
451. 3 on bone metabolism in patients treated with phenobarbitone/phenytoin
452. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry
453. Effect of carbamazepine and valproate on bone mineral density
454. Valproate clincial use
455. Renal toxicity induced by valproic acid
456. Reversible Fanconi syndrome associated with valproate therapy
457. Valproic acid: A possible cause of proximal tubular renal syndrome
458. Lithium and symptomatic hyperparathryroidism
459. Lithium, hypercalcemia and hyperparathyroidism
460. Endocrine effects of lithium. II. Primary hyperparathyroidism
461. Long-term lithium carbonate therapy causes hyperparathyroidism
462. Hypothyroidism and hyperparathyroidism associated with lithium
463. Hyperparathyroidism in association with lithium therapy
464. Effects of lithium carbonate on human calcium metabolism
465. Alterations in parathyroid dynamics in lithium-treated subjects
466. Renal function on and off lithium in patients treated with lithium for 15 years or more: A controlled, perspective lithium-withdrawal study
467. Hyperparathyroidism, hypothyroidism, and impaired renal function after 10 to 20 years of lithium treatment
468. Osteopenia and dysregulation of divalent cations in lithium-treated patients
469. Lithium-induced alterations in parathyroid cell function: Insight into the pathogenesis of lithium-associated hyperparathyroidism
470. Investigation of calcium-induced hydrolysis of phosphoinositides in normal and lithium-treated parathyroid cells
471. Effects of high extracellular Calcium concentrations of phosphoinositide turnover and inositol phosphate metabolism in dispersed bovine parathyroid cell
472. Lithium-induced hyperparathyroidism: An alteration Of the 'set-point'
473. The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo
474. Lithium stimulates the release of human parathyroid hormone in vitor
475. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells
476. Effect Of lithium on the metabolic response to parathyroid hormone
477. Effects of lithium therapy on bone mineral metabolism: A two-year prospective longitudinal study
478. The parathyroid hormone circadian rhythm is truly endogenoous: A general clinical research center study
479. Lithium's effect on parathyroid hormone
480. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up)
481. Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy
482. Sodium etidronate in the treatment of Paget's disease of bone: A study of long-term results
483. Osteoblasts mediate the bisphosphonate inhibition Of bone resorption through synthesis of an osteoclast-inhibiting activity
484. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease
485. Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis
486. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: The Alendronate phase II Osteoproosis Treatment Study Group
487. Three-year treatment of osteoporosis with alendronate: Effect on vertebral fracture incidence
488. Alendronate for osteoporosis: Safe and efficacious nonhormonal therapy
489. Effect of combined therapy with sodium fluoride, vitamin D, and calcium in osteoporosis
490. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: Comparison with conventional therapy
491. Fluoride in medicine
492. Drug-induced osteomalacia
493. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis
494. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
495. Clinical trial of fluoride therapy in postmenopausal women: Extended observations and additional analysis
496. Continuous sodium fluoride therapy does not reduce vertebral fracture rate in postmenopausal osteoporosis
497. HIstomorphometric analysis of a calcaneus stress fracture: A possible complication of fluoride therapy for osteoporosis
498. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: Final report of a randomized controlled trial
499. Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis
500. The effect of intermittent slow-release sodium fluoride and continuous calcium citrate therapy on calcitropic hormones, biochemical markers of bone metabolism, and blood chemistry in postmenopausal osteoporosis
501. Efficacy of therapy of involutional osteoporosis with disodium monofluorophosphate and calcium [abstract]
502. Monoflorophosphate increases lumbar bone density in osteopenic patients: A double-masked randomized study
503. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: The FAVO Study
504. 3 in treatment of ostemalacia associated with ileal resection and cholestyramine therapy
505. Osteomalacia associated with cholestyramine therapy for postiliectomy diarrhea
506. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis
507. Saccharated ferric oxide (SFO)-induced osteomalacia: In vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules
508. Three cases of osteomalacia caused by intravenous administration of saccharated ferric oxide
509. A case of osteomalacia caused by intravenous administration of saccharated ferric oxide
510. Effect of intravenous infusion of saccharated ferric oxide in hypophosphatemia
511. Two cases of nonspecific ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide
512. A case of osteomalacia due to secondary hemochromatosis
513. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide